Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 784459 10.3389/fphar.2022.784459 Pharmacology Review Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin Bailey and Gwilt Covid-19, Diabetes and Metformin Bailey Clifford J. * Gwilt Mike Life and Health Sciences, Aston University, Birmingham, United Kingdom

Edited by: Saibal Das, Indian Council of Medical Research (ICMR), India

Reviewed by: Maha Mohamed Saber-Ayad, University of Sharjah, United Arab Emirates

Jayanta Dey, Nil Ratan Sircar Medical College and Hospital, India

 *Correspondence: Clifford J. Bailey, c.j.bailey@aston.ac.uk

This article was submitted to Pharmacoepidemiology, a section of the journal Frontiers in Pharmacology

 09 03 2022 2022 13 784459 27 09 2021 21 02 2022 Copyright © 2022 Bailey and Gwilt. 2022 Bailey and Gwilt

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Objectives: Pre-existing or new diabetes confers an adverse prognosis in people with Covid-19. We reviewed the clinical literature on clinical outcomes in metformin-treated subjects presenting with Covid-19.

Methods: Structured PubMed search: metformin AND [covid (ti) OR covid-19 (ti) OR covid19 (ti) OR coronavirus (ti) OR SARS-Cov2 (ti)], supplemented with another PubMed search: “diabetes AND [covid OR covid-19 OR covid19 OR coronavirus (i) OR SARS-Cov2 (ti)]” (limited to “Clinical Study”, “Clinical Trial”, “Controlled Clinical Trial”, “Meta-Analysis”, “Observational Study”, “Randomized Controlled Trial”, “Systematic Review”).

Results: The effects of metformin on the clinical course of Covid-19 were evaluated in retrospective analyses: most noted improved clinical outcomes amongst type 2 diabetes patients treated with metformin at the time of hospitalisation with Covid-19 infection. These outcomes include reduced admission into intensive care and reduced mortality in subgroups with versus without metformin treatment.

Conclusion: The pleiotropic actions of metformin associated with lower background cardiovascular risk may mediate some of these effects, for example reductions of insulin resistance, systemic inflammation and hypercoagulability. Modulation by metformin of the cell-surface ACE2 protein (a key binding target for SARS-CoV 2 spike protein) via the AMP kinase pathway may be involved. While pre-existing metformin treatment offers potentially beneficial effects and can be continued when Covid-19 infection is not severe, reports of increased acidosis and lactic acidosis in patients with more severe Covid-19 disease remind that metformin should be withdrawn in patients with hypoxaemia or acute renal disease. Prospective study of the clinical and metabolic effects of metformin in Covid-19 is warranted.

 Graphical Abstract

type 2 diabetes metformin COVID—19 safety SARS—CoV—2 Introduction

Covid-19 has infected millions of people world wide (Covid live, 2021), and it is well recognised that people with type 2 diabetes are more susceptible to Covid19 infection and worse outcomes (Apicella et al., 2020; Feldman et al., 2020). A growing evidence base of real-world studies has explored the effects of diabetes and metformin, the most commonly used treatment in type 2 diabetes, on the clinical course of Covid-19. We have reviewed the current literature on this topic and summarised the latest data on the impacts of diabetes and metformin on Covid-19 outcomes to derive pragmatic proposals for when to continue or withdraw treatment with metformin.

 Methods

This review is based on a structured literature search. Studies on the effects of metformin on outcomes in people infected with Covid-19 were identified by searching PubMed using the following search string: metformin AND (covid [ti] OR covid-19 [ti] OR covid19 [ti] OR coronavirus [ti] OR SARS-Cov2 [ti]), and diabetes AND (covid OR covid-19 OR covid19 OR coronavirus [ti] OR SARS-Cov2 [ti]); the second search was limited to “Clinical Study, Clinical Trial, Controlled Clinical Trial, Meta-Analysis, Observational Study, Randomized Controlled Trial, and Systematic Review” to exclude general reviews and limit the number of search hits. The 132 hits (April 14 2021) were examined for relevance. Reviews and systematic reviews were checked for additional references. Studies on the pleiotropic properties of metformin were from the reviews cited.

 Diabetes and Covid-19 Outcomes Prognosis in Patients With Covid-19 Complicated by Diabetes

Diabetes, among other comorbidities, increases the risk of a serious adverse prognosis for people who contract Covid-19, as shown by numerous individual studies, meta-analyses and systematic reviews (Figure 1). (Zhang et al., 2020a; Ciceri et al., 2020; Yu et al., 2020; Zhou et al., 2020; Barron et al., 2020; Abu-Jamous et al., 2021; Lee et al., 2020; Wu J. et al., 2020; Fox et al., 2021; Chilimuri et al., 2020; Guan W. J. et al., 2020; Zhu et al., 2020; Yan et al., 2020; Petrilli et al., 2020; Al-Salameh et al., 2021; Shang et al., 2021; Xu et al., 2020; Kim et al., 2020; Liu et al., 2020; Docherty et al., 2020; Shi et al., 2020; Smith et al., 2020; Saha et al., 2021; Liu et al., 2021; Kaminska et al., 2021; Elezkurtaj et al., 2021; Corona et al., 2021; Sun et al., 2021; Bud et al., 2020; Palaiodimos et al., 2020; Miller et al., 2020; Varikasuvu et al., 2021; Hussain et al., 2020; Shang et al., 2020; Guo L. et al., 2020; Aggarwal et al., 2020; Zaki et al., 2020; Parveen et al., 2020; Wu et al., 2021; Mantovani et al., 2020; Huang I. et al., 2020; Kumar et al., 2020; Roncon et al., 2020) Populations of patents hospitalised or entering intensive care for Covid-19 include a relatively high prevalence of diabetes, typically 1.5-3 fold greater than similar populations without diabetes (Carey et al., 2018; Abdi et al., 2020; Apicella et al., 2020; Bhatti et al., 2020; Wu C. et al., 2020; Hussain et al., 2020; Sathish and Cao, 2021; Sathish et al., 2021). Greater hyperglycaemia immediately prior to and during hospitalisation has consistently been associated with increased severity of Covid-19 infection in adults of any age with type 1 and type 2 diabetes, and especially in younger adults (<50 years of age) (Ando et al., 2021; Diedisheim et al., 2021; Gregory et al., 2021; Rawshani et al., 2021). The increased severity of Covid-19 infection in adults with diabetes has been noted irrespective of gender, ethnicity and geographical region (Ando et al., 2021; Diedisheim et al., 2021; Gregory et al., 2021; Rawshani et al., 2021).

Impact of comorbid diabetes on the risk of mortality from Covid-19. Studies reporting morality outcomes [or composite of death, renal replacement therapy/haemodialysis, ventilation, intubation or use of vasopressor (Abu-Jamous et al., 2021)] are hazard ratios [HR (Zhang et al., 2020a; Barron et al., 2020; Ciceri et al., 2020; Yu et al., 2020; Zhou et al., 2020; Abu-Jamous et al., 2021)], odds ratios [OR (Guan W. J. et al., 2020; Wu J. et al., 2020; Chilimuri et al., 2020; Docherty et al., 2020; Kim et al., 2020; Lee et al., 2020; Liu et al., 2020; Petrilli et al., 2020; Shi et al., 2020; Xu et al., 2020; Yan et al., 2020; Zhu et al., 2020; Al-Salameh et al., 2021; Fox et al., 2021; Shang et al., 2021)], or relative risks [RR (Smith et al., 2020)] after stratification of populations for the presence or absence of diabetes are shown here. Diabetes was not stratified into types 1 and 2, except where stated.

In addition to escalating the hyperglycaemia in diabetes patients it is noted that newly-diagnosed diabetes is a common finding among people admitted for Covid-19, consistent with population-based surveys reporting a high prevalence of undiagnosed diabetes (Chou et al., 1994; Centers for Disease Control, 2020). The prevalence of diabetes is higher in older than younger patients with Covid-19, as would be expected, which has relevance for the clinical management of this population (Desai et al., 2020).

Figure 1 shows the risk of death from Covid-19 according to the presence versus absence of diabetes from retrospective studies. Overall, the risk of death from Covid-19 appeared to be at least doubled when diabetes was present. The risk of Covid-19 mortality in people with type 1 diabetes has been higher than with type 2 diabetes in some studies, but this has not been a consistent finding (Barron et al., 2020; Rawshani et al., 2021). However, an approximately ten-fold higher prevalence of type 2 versus type 1 diabetes ensures that the majority of deaths among people with diabetes occur in those with the type 2 form. Diabetes also increases the risk of other serious adverse Covid-19 outcomes, including development of severe respiratory distress, pneumonia and a need for treatment in the intensive care unit (ICU), assisted ventilation, or more drug therapies (Apicella et al., 2020; Seiglie et al., 2020; Zhu et al., 2020).

Diabetes is associated with a range of cardiovascular risk factors, including overweight or obesity, systemic inflammation, insulin resistance, hypertension and a procoagulant state, as well as their clinical sequelae, notably coronary heart disease, heart failure and stroke (Dokken, 2008). Diabetes is also associated with an increased risk of chronic kidney disease and chronic obstructive pulmonary disease which are commonly encountered in patients with severe Covid-19 infection. Figure 2 shows the average levels of biomarkers of inflammation and hypercoagulability in patients with type 2 diabetes who either died from or survived Covid-19 (Xu et al., 2020). Many of these co-morbidities have themselves been associated with increased risk of serious adverse Covid-19 outcomes (Shi et al., 2020; Abu-Jamous et al., 2021), and the co-morbidities that commonly accompany diabetes are deemed to be at least partially additive to the metabolic disturbances of diabetes that aggravate the course of Covid-19 infection (Abdi et al., 2020; Ando et al., 2021; Diedisheim et al., 2021; Gregory et al., 2021; Rawshani et al., 2021). For example, the risks of ICU admission, need for ventilation and death increased as weight category increased (normal weight, overweight and obesity), and a diagnosis of diabetes conferred additional risk at each weight category (Seiglie et al., 2020). However, the presence of diabetes per se appears to impair the prognosis in people with Covid-19, in the absence of other comorbidities (Guo W. et al., 2020).

Markers of systemic inflammation and blood coagulability in patients with or without type 2 diabetes who died from Covid-19. Data are medians and interquartile ranges. Drawn from data presented by Xu et al., 2020.

 Mechanisms for the Interaction of Covid-19 With Diabetes

Mechanisms through which the metabolic disturbances of diabetes increase the severity of Covid-19 infection have recently been reviewed in detail (Lim et al., 2021). The pro-inflammatory environment of obese and diabetic states facilitates an exaggerated cytokine response (cytokine storm) as noted with excessive plasma concentrations of C-reactive protein, interleukin-6, tumour necrosis factor-alpha, monocyte chemoattractant protein-1 and interferon-gamma in diabetes patients with severe Covid-19 infection (Gianchandani et al., 2020; Roberts et al., 2020; Zhu et al., 2020; Lim et al., 2021). Lymphocyte counts are notably reduced in diabetes patients with severe Covid-19 infection, particularly associated with greater hyperglycaemia (Zhang et al., 2020a; Gianchandani et al., 2020; Zhu et al., 2020; Zhang et al., 2021), and the effect of inflammatory cytokines to promote insulin resistance increases the hyperglycaemia in diabetes patients (Chen et al., 2015). Cellular damage by the viral infection, particularly inducing apoptosis, is aggravated by hyperglycaemia through increased reactive oxygen species, and there is evidence that the pro-coagulant state in diabetes promotes the thrombotic effects of severe Covid-19 infection (Feldman et al., 2020; Roberts et al., 2020; Singh et al., 2020; Lim et al., 2021). Severe Covid-19 infection is also prone to escalate inflammatory and fibrotic lesions, especially in lungs, heart, skeletal muscle and kidneys, which appear to confer lasting adverse effects (long-Covid) (Madjid et al., 2020; Raveendran and Misra, 2021). Expression of ACE2 by pancreatic beta-cells contributes to the susceptibility of these cells to Covid-19 attack, interrupting insulin secretory activity and accentuating hyperglycaemia (Feldman et al., 2020; Lim et al., 2021; Müller et al., 2021).

Whether possible alterations of ACE2 expression during antihypertensive treatment with ACE inhibitors and angiotensin receptor blockers could affect viral entry and transmission around the body remains unclear (Roberts et al., 2020). Overall, it is evident that diabetes and Covid-19 infection can create a vicious spiral in which the Covid-19 infection makes the diabetes worse and the diabetes makes the Covid-19 infection worse.

 Importance of Glycaemic Control

Blood glucose control seems to be important for the prognosis of Covid-19 infection: a study using propensity scoring to closely match two groups of 250 people with diabetes for cardiometabolic risk factors other than glycaemia (hypertension, cardiovascular disease, cerebrovascular disease, chronic kidney disease and diabetes duration) showed that good blood glucose control (3.9–10.0 mmol/L) vs. suboptimal blood glucose control decreased the risk of Covid-19 mortality by about 7-fold [HR 0.14 (95%CI 0.03, 0.60), p = 0.008] (Zhu et al., 2020). The well-controlled group also needed less treatment with antifungal agents, antibiotics, immunoglobulins, steroids, oxygen, and assisted ventilation. In addition, better glucose control has been associated with lower levels of markers of systemic inflammation (e.g., neutrophil count, IL-6 and C-reactive protein) and better immune function (higher lymphocyte count) (Huang Y. et al., 2020; Xu et al., 2020). In another study, people with diabetes and average blood glucose above versus below 7.8 mmol/L have been shown to require more treatment in the ICU and longer use of mechanical ventilation (Saand et al., 2021).

Registry studies have identified hyperglycaemia at admission as a significant, independent predictor of Covid-19 hospitalisation or mortality (O'Malley et al., 2021; Carrasco-Sánchez et al., 2021). The severity of hyperglycaemia appears to influence prognosis, appreciating that blood glucose can rise quickly during Covid-19 infection as seen with plasma glucose measurements but not with the gradual effect on HbA1c (Zhang Q. et al., 2020; Wang B. et al., 2021; Ling et al., 2021). Hyperglycaemia is associated with adverse Covid-19 outcomes whether or not patients have diabetes (Cai et al., 2020; Carrasco-Sánchez et al., 2021), with some suggestion of a more severe effect on Covid-19 prognosis for newly-diagnosed versus pre-existing diabetes, possibly associated with depressed respiratory function (Aggarwal et al., 2020; Fadini et al., 2020). For example, “secondary hyperglycaemia” (no diabetes history, fasting plasma glucose ≥7 mmol/L but HbA1c <6.5%) was associated with a doubling of the risk of a composite outcome of Covid-19 severity compared with pre-existing diabetes after hospitalisation for Covid-19 (Zhang et al., 2020b). Indeed, higher fasting glucose in Covid-19 patients without diabetes predicted increased circulating levels of inflammatory markers and reduced lymphocyte counts, which were in turn associated with a higher risk of mortality (Huang Y. et al., 2020).

 Impact of Covid-19 on Glycaemia

Covid-19 may exacerbate suboptimal blood glucose control in diabetes, as shown by a recent meta-analysis in which Covid-19 increased blood glucose by 2.2 mmol/L, on average (Chen J. et al., 2020). However, much greater effects on blood glucose are possible, as illustrated by a case report concerning a man with well-controlled metformin-treated type 2 diabetes (HbA1c 6.1%) who developed severe Covid-19 requiring ICU admission and assisted ventilation (Jornayvaz et al., 2020). His blood glucose rose to 15 mmol/L in the days following ICU admission, despite receiving 50 U/hour of rapid-acting insulin. This extreme manifestation of insulin resistance was unexplained, but may have been associated with severe systemic inflammation during a cytokine storm, which is recognised increasingly as an important component of the pathogenesis of life-threatening complications of Covid-19 (Chen and Quach, 2021).

 Metformin and Covid-19 Metformin and Risk of Covid-19 Infection

A study of propensity score-matched cohorts of T2D patients receiving metformin or not receiving metformin in The Health Improvement Network (a United Kingdom primary care database, N = 10,183 for each cohort) reported similar hazard ratios [HR (95%CI)] between groups for development of suspected/confirmed Covid-19 [0.85 (0.67, 1.08)], or confirmed Covid-19 [0.80 (0.49, 1.30)] (Wang J. et al., 2021). A study from Korea (N = 11,892 people with T2D matched for use or non-use of metformin using propensity scoring) found a small, but significant, reduction in the risk of contracting Covid-19 in the metformin group [OR 0.88 (0.78, 0.99), p = 0.039] (Oh and Song, 2021). Overall, therefore, large database studies do not suggest a major influence of metformin on the risk of contracting Covid-19.

 Metformin and Severity of Covid Infection

Evaluations of the effects of metformin on clinical outcomes in people who develop Covid-19 have been of a retrospective design at this time, by necessity. Table 1 summarises findings from cohorts of outpatients who developed Covid-19 (some of whom were subsequently hospitalised for this condition) (Crouse et al., 2020; Do et al., 2020; Bramante et al., 2021a; Abu-Jamous et al., 2021; Wang J. et al., 2021; Ghany et al., 2021; Lally et al., 2021; Oh and Song, 2021) Several studies in outpatient populations demonstrated reduced risks of serious adverse outcomes such as hospitalisation or death due to Covid-19 in cohorts receiving versus not receiving metformin (Crouse et al., 2020; Do et al., 2020; Bramante et al., 2021a; Ghany et al., 2021; Lally et al., 2021). One of these studies demonstrated reduced mortality when metformin was prescribed only after testing positive for Covid-19 (Abu-Jamous et al., 2021). No significant influence of metformin treatment was seen in other studies (Do et al., 2020; Wang J. et al., 2021; Oh and Song, 2021).

Overview of retrospective studies of the effect of metformin in people who became infected with SARS-Cov2 (Covid-19).

Ref Design/patients Summary of main findings in patients with Covid-19
Studies in outpatients
  Abu-Jamous et al. (2021) 456 inpatients with diabetes a , b Reduced risk of death [0.19 (0.05, 0.70)] in diabetes patients who initiated “biguanide” (i.e. metformin) only after testing positive for Covid-19 (compared with patients who never received treatment)
  Wang J. et al. (2021) 20,366 with T2D No reduction in Covid-19 mortality in propensity score-matched cohorts of metformin users vs. non-users [HR: 0.87 (0.34, 2.20)]
  Oh and Song, (2021) 11,892 with T2D No effect of metformin on subsequent in-hospital Covid-19 mortality [OR 1.26 (0.81, 1.95), 0.301] between propensity-score matched cohorts of metformin users vs. non-users
  Ghany et al. (2021) 1,139 US Medicare Reduced RH for hospitalisation [0.71 (0.52, 0.86)], death [0.34 (0.19, 0.59)], ARDS [0.32 (0.22, 0.45)] for N = 392 on metformin vs. non-metformin, including patients without diabetes
  Bramante et al. (2021a) 9,555 overweight subjects c Metformin use (N = 676) vs. no metformin (N = 8,879) was associated with reduced mortality [OR 0.32 (0.15, 0.66), p = 0.002] and trends to reduced hospitalisation [OR 0.78 (0.58, 1.04) p = 0.087] and ICU admission [OR 0.68 (0.45, 1.02), p = 0.060]. Outcomes in 342 pairs of propensity score-matched metformin users and non-users were similar
  Lally et al. (2021) 775 nursing home residents Reduced risk of death [HR 0.48 (0.28, 0.84)] for metformin (N = 127) vs. no glucose-lowering drug (N = 476); no significant benefit for insulin or other glucose-lowering drug
  Do et al. (2020) 1,865 with diabetes No mortality difference between 469 metformin users and 95 non-users [HR 0.77 (0.44, 1.35), p = 0.052]. Mortality was higher for no metformin vs. no AD [HR 1.79 (1.04, 3.10), p = 0.036], but not for metformin vs. no glucose-lowering drug [HR 1.38 (0.97, 1.97), p = 0.076]
  Crouse et al. (2020) 604 inpatients a Metformin use vs. non-use among people with diabetes was associated with reduced mortality [OR 0.33 (0.13, 0.84), p = 0.0210] in people who tested positive for Covid-19 while in hospital for other reasons
Patients hospitalised for Covid-19
  (Li et al., 2020; Li et al., 2021) 131 with T2D Overall, 85% recovered, 15% died. Reduced mortality vs. overall cohort in N = 37 receiving metformin (95% recovered/5% died, p = 0.02), N = 57 receiving acarbose (91% recovered/8% died, p = 0.04), or N = 13 who received both (all survived, p-0.03). No significant effect of other glucose-lowering drug (alone or in combination). Glucose-lowering drug use was maintained after hospitalisation for Covid-19 d
  Cheng et al. (2021) 407 with T2D Reduced ICU admission for pre-admission metformin (N = 18) vs. no metformin (N = 32; 5.6 vs. 43.8%, p = 0.005). No significant difference between metformin and non-metformin groups in hospital. Non-significant trend to reduced mortality and need for invasive ventilation for metformin vs. non-metformin. No benefit for insulin vs. no insulin (trend towards adverse outcomes)
  Bramante et al. (2021b) 6,255 with T2D or obesity Reduced mortality with metformin in women [HR 0.785 (0.650, 0.951)] but not in men [HR 0.957 (0.82, 1.14), p = 0.689] or overall (HR 0.887 [0.782, 1.008]). Results from propensity score-matched cohorts were similar
  Jiang et al. (2021) 328 with T2D Reduced risk of ARDS for 100 metformin users vs. 228 non-users [OR 0.18 (0.05, 0.62), p = 0.007]; no significant effect on severity of Covid-19 or on 30-day mortality
  Lalau et al. (2021) 2,449 with T2D Reduced risk at 28 days post-admission of a composite of tracheal intubation or death [OR 0.783 (0.615, 0.996)] or death [OR 0.710 (0.537, 0.938)] for 1,496 metformin users vs. 953 non-users
  Wargny et al. (2021) 2,796 with T2D Metformin therapy was a significant predictor of earlier discharge (along with longer duration of symptoms): OR 1.40 (1.08, 1.81) for discharge within 28 d in the metformin vs. non-metformin group OR 1.40 (1.08, 181). Metformin was associated with reduced risk of death within 28 d 0.65 (0.45, 0.93)
  Gao et al. (2020) 110 with T2D More (p = 0.004) life-threatening complications in 56 metformin users (29%) vs. 54 non-metformin users (7.4%), with higher risk of disease progression during hospitalization [OR 3.964 (1.034, 15.194), p = 0.045]
  Cheng et al. (2020) 1,213 with T2D No effect of metformin (N = 678) vs. non-metformin (N = 535) on 30 day mortality [HR 1.65 (0.71, 3.86), p = 0.247]. Metformin was associated with less HF [HR 0.59 (0.41, 0.83), p = 0.003] but more acidosis [HR 2.73 (1.04, 7.13), p = 0.040], including lactic acidosis [HR 4.46 (1.11, 18.00), p = 0.036]; no difference for ARDS, DIC, AKI, acute heart injury
  Luo et al. (2020) 283 with diabetes Less (p = 0.01) in-hospital mortality for 104 metformin users (2.9%) vs. 179 non-users (12.3%); no difference for LOS.
  Nafakhi et al. (2021) 192 with Covid-19 pneumonia Metformin (and DPP4 inhibitor) associated with reduced overall LOS and LOS in the ICU.
  Pérez-Belmonte et al. (2020) 2,666 with diabetes e No association of metformin or other glucose-lowering drug with risk of mortality, composite ICU admission, mechanical ventilation, or in-hospital mortality, other complications in hospital, or LOS.
  Chen Y. et al. (2020) 120 with diabetes e No significant effect of metformin in in-hospital mortality, LOS, or assessment of poor prognosis

Included in this part of the table because they were not hospitalised for Covid-19; 93% of the metformin group had T2D.

From 1,253 positive results for SARS-CoV2 among 5,294 screened on admission to hospital for various causes.

BMI >25 kg/m2.

Before/after hospitalisation: metformin N = 37/37, acarbose N = 38/57.

In the SEMI-COVID registry.AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; DIC, disseminated intravascular coagulation; HF, heart failure; HR, hazard ratio; ICU, intensive care unit; LOS, length of (hospital) stay; OR, odds ratio; RH, relative hazard; T2D, type 2 diabetes; vs.: versus. Figures in square brackets are 95% Confidence Intervals.

The populations of the studies described all had type 2 diabetes, while other cohorts were selected for being overweight or obese (Bramante et al., 2021a), resident in a nursing home (Lally et al., 2021), an elderly US Medicare population (Ghany et al., 2021), or positive during screening for Covid-19 when hospitalised for other causes (Crouse et al., 2020), in each case with or without concomitant diabetes. Most metformin-treated patients with diabetes had type 2 diabetes as would be expected (84–99% of patients in studies where this information was provided (Bramante et al., 2021a; Ghany et al., 2021; Lally et al., 2021); thus, these studies involved comparison of a metformin group (mostly) with type 2 diabetes with a comparator group containing fewer patients with type 2 diabetes. Given that a diagnosis of diabetes is associated with a poorer prognosis in people with Covid-19 (see above), it is possible that a beneficial effect of treatment with metformin may have outweighed the potentially adverse influence of a higher prevalence of diabetes in the metformin versus non-metformin groups.

Table 1 also summarises the main findings of retrospective studies in patients identified at the time of admission to hospital for Covid-19 (Chen Y. et al., 2020; Cheng et al., 2020; Gao et al., 2020; Li et al., 2020; Luo et al., 2020; Pérez-Belmonte et al., 2020; Bramante et al., 2021b; Cheng et al., 2021; Jiang et al., 2021; Lalau et al., 2021; Li et al., 2021; Nafakhi et al., 2021; Wargny et al., 2021). Most of these studies demonstrated improved clinical outcomes in cohorts of patients who did versus did not receive metformin, including reductions in mortality, lesser need for highly intensive treatment [e.g., admission to the intensive care unit (ICU) or assisted ventilation], or reduced onset of acute respiratory distress syndrome (ARDS) (Cheng et al., 2020; Gao et al., 2020; Li et al., 2020; Luo et al., 2020; Bramante et al., 2021b; Cheng et al., 2021; Jiang et al., 2021; Lalau et al., 2021; Li et al., 2021; Wargny et al., 2021). One study reported that metformin reduced mortality only in women, with no significant effect in men, or in the overall population (Bramante et al., 2021b). There was more acidosis (including lactic acidosis) in metformin users than in non-users in another study, although mortality was unaffected and there was an apparent reduction in the frequency of heart failure in the metformin group (Cheng et al., 2020). The increased risk of acidosis could be due in part to accumulation of excess plasma metformin consequent to a rapid deterioration in renal function noted in more than 20% of patients with severe Covid-19 infection (Nadim et al., 2020). Acute renal failure is a contraindication that requires discontinuation of metformin as discussed later. A small study (113 subjects) reported an increase in life threatening complications of Covid-19 associated with metformin treatment during the hospital stay (Gao et al., 2020).

Systematic or pooled analyses that include studies listed in Table 1 provided similar results. A meta-analysis of 5 comparisons of metformin with a control group showed that metformin reduced mortality before [OR 0.45 (0.25, 0.81), p = 0.008] and after multivariable adjustment [OR 0.64 (0.43, 0.97), p = 0.035] in people with Covid-19 (Lukito et al., 2020). Another meta-analysis, reported as a letter to a journal, reported similar findings [OR for mortality 0.62 (0.43, 0.89) for metformin versus no metformin in this population] (Kow and Hasan, 2021). A systematic review concluded that metformin was associated with improved Covid-19 outcomes in 9/14 studies that recruited populations with or without diabetes (Zangiabadian et al., 2021).

Metformin is often used off-label in the management of prediabetes and polycystic ovary syndrome (Hostalek et al., 2015; Guan Y. et al., 2020; Hostalek and Campbell, 2021). Database analyses to specifically assess the effect of metformin on the severity of Covid-19 infections in these conditions have not been reported. However, it is possible that the actions of metformin that curb the severity of Covid-19 infection in type 2 diabetes might confer similar benefits to individuals receiving metformin for other conditions.

 Possible Mechanisms for Metformin on Severity of Covid Infection

Cardiovascular comorbidities increase the risk of severe, adverse Covid-19 outcomes, as described above. Metformin has been shown to reduce the risk of cardiovascular events and to increase survival in populations with type 2 diabetes in the randomised United Kingdom Prospective Diabetes Study (UKPDS) (UK Prospective Diabetes Study Group, 1998) and in large meta-analyses that included real world, observational data (Han et al., 2019; Zhang K. et al., 2020). Thus, reduced cardiometabolic comorbidities may explain, at least in part, the way in which metformin can improve the prognosis of people with Covid-19. A potential vascular benefit of metformin relates to the thrombotic effects of Covid-19 infection. Metformin is known to exert thrombolytic effects by reducing platelet aggregation, reducing the production of plasminogen-activator inhibitor-1 and altering fibrin structure as summarised in Figure 3 and described in detail elsewhere (Grant, 2003; Xin et al., 2016).

Schematic summary of antithrombotic effects of metformin (shown in red). See text for references. PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen activator.

 Metformin Anti-Inflammatory Effects

The cellular mechanisms underlying metformin’s cardioprotective effect are likely to extend beyond its antihyperglycaemic effect (Campbell et al., 2017; Petrie et al., 2020). They include amelioration of several metabolic abnormalities, including insulin resistance (Du et al., 2013), hypercoagulability of the blood (Grant, 2003; Markowicz-Piasecka et al., 2020), and increased levels of markers of systemic inflammation (Saisho, 2015; Bai and Chen, 2021)that have been described in patients who progress to severe Covid-19 (Figure 2). (Zhu et al., 2020; Xu et al., 2020; Huang I. et al., 2020; Zhang Q. et al., 2020; Wargny et al., 2021; Govender et al., 2021; Wang et al., 2020) Accordingly, actions of metformin to reduce these risk factors may provide further explanation for at least some of the apparent benefit of metformin treatment in patients with Covid-19 (Figure 4). Indeed, lower circulating levels of inflammatory markers have been observed in metformin-treated patients with Covid-19, compared with non-metformin control groups (Chen Y. et al., 2020; Cheng et al., 2020; Al-Kuraishy et al., 2021).

Summary of the potential mechanisms by which metformin might influence the course of severe Covid-19 infection. ICU, intensive care unit; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease. See text for references. Image of coronavirus by permission of US Centers for Disease Control (https://www.cdc.gov/media/subtopic/images.htm).

Inhibition of the mitochondrial respiratory chain at complex I by metformin increases the ratio of cellular ADP and AMP to ATP, which in turn activates the AMP-activated protein kinase (AMPK) pathway (Figure 5). (Vial et al., 2019) Metformin can also activate AMPK independently of adenine nucleotides (Hawley et al., 2002). Increased activity of AMPK will suppress signalling of the nuclear transcription factor, NFκB, mediated via downstream targets that include Forkhead box O (FoxO), peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α), tumour suppressor protein p53 and sirtuin-1 (Salminen et al., 2011). Suppression of NFκB signalling in turn reduces the production of inflammatory cytokines, notably interleukin-6 and TNFα, and this is deemed likely to explain much of the anti-inflammatory effect of metformin (Liu et al., 2017).

Summary of anti-inflammatory mechanisms of metformin arising via activation of the AMP kinase pathway. See text for references. NO, nitric oxide; TNFα, tumour necrosis factor alpha.

 Metformin Anti-Viral Effects

Activation of AMPK by metformin also increases phosphorylation of the S680 serine residue of the ACE2 protein (Figure 4). (Zhang et al., 2018) ACE2 acts as a cell membrane enzyme and receptor which mediates endocytotic internalisation of the SARS-CoV2 virus by binding its spike protein. Phosphorylation of ACE2 is anticipated to alter the conformation of this molecule, which may reduce the binding of SARS-CoV2 virions at the cell membrane and thus impede access to the cell, representing a potential anti-Covid-19 mechanism of metformin (Malhotra et al., 2020). However, S680 phosphorylation of ACE2 may also slow the degradation of ACE2, potentially increasing its concentration. Plasma ACE2 promotes antihypertensive and anti-inflammatory effects via the production of angiotensin-(1–7) which then acts via the Mas receptor (Rodrigues Prestes et al., 2017; Rukavina Mikusic et al., 2021). This provides a further possible route through which metformin might reduce the pathology of Covid-19 infection (Vial et al., 2019). Figure 5 summarises potential mechanisms by which metformin may improve outcomes in people with Covid-19.

More speculatively, antiviral properties have been attributed to molecules containing a biguanide moiety, including metformin (Kathuria et al., 2021). Indeed, metformin was used in the management of influenza in 1950 (when it was known as “flumamine”), 7 years before its entry into clinical use for type 2 diabetes (Bailey et al., 2007). Further clinical research will be needed to define and quantify any potentially beneficial anti-viral effects of metformin specifically related to the course of infection with SARS-CoV2.

 Looking Ahead: Should Metformin Be Discontinued With Covid-19 Infection

Most studies described above reported either no effect, or a potential benefit, on clinical outcomes associated with pre-existing metformin treatment after contracting Covid-19. These data are all retrospective, however, which limits their utility for guiding future practice. Also, important information is lacking at this time, for example relating to exactly when, and for whom, metformin may have been withdrawn during hospitalisation. In addition, only observational data on the effects of metformin in people with Covid-19 are available at present, and such data need to be interpreted with caution, due to risk of confounding. Appropriately designed clinical trials are needed to explore the reasons for the apparent amelioration of the course of Covid-19 infection in metformin treated type 2 diabetes subjects in the retrospective studies described herein.

The two studies that suggest potential harms of metformin treatment on outcomes in patients hospitalised for Covid-19 (Cheng et al., 2020; Gao et al., 2020) are of particular interest in evaluating the safety of metformin for people with type 2 diabetes who develop Covid-19. In one study in people with type 2 diabetes, the prevalence of life-threatening complications of Covid-19 was rare at admission (1.8% in the metformin group, and 0% in the control group) (Gao et al., 2020). However, during the stay in hospital 29% of the metformin group and only 7% of the control group required ICU admission (p = 0.004), with a 4-fold increase in the risk of life-threatening complications in the metformin vs. non-metformin groups (Gao et al., 2020). The second study demonstrated an association of metformin treatment with a 2.5-fold increased risk of acidosis (p = 0.032) and a 4.7-fold increase in lactic acidosis (p = 0.010) during hospitalisation for Covid-19 (Cheng et al., 2020). Moreover, these risks were much higher where renal function was compromised (eGFR <60 ml/min/1.73 m2; risk increases 5.2- and 3.9-fold for acidosis and lactic acidosis, respectively), or when metformin was given at a high dosage (2–3 g/day; risk increases 12.8- and 22.6-fold for acidosis and lactic acidosis, respectively). The acute decline in renal function that affects >20% of hospitalized patients with Covid-19 infection and >50% of patients admitted to ICU (Nadim et al., 2020) is therefore a particular caution for continued use of metformin. It is generally recommended that the dose of metformin should not exceed 1,000 mg/day if GFR declines to below 45 ml/min/1.73 m2, and metformin should be discontinued if the GFR declines to below 30 ml/min/1.73 m2. Accumulation of excess metformin that occurs when drug elimination is impeded by renal impairment is likely to make an important contribution to the risk of acidosis, and especially lactic acidosis due to increased metformin-associated anaerobic metabolism. Anaerobic metabolism will also aggravate the hypoxemia of acute respiratory distress and this represents another caution for discontinuation of metformin.

Acute metabolic acidosis, conditions with the potential to impair renal function (including severe infection) or tissue hypoxia (including respiratory failure or severe congestive heart failure) are all contra-indications for treatment with metformin, which were put in place to minimise the risk of lactic acidosis with this treatment (DeFronzo et al., 2016). Nevertheless, metformin treatment appears to be generally safe for most people in the early stages of Covid-19 infection, according to the data summarised above. However, withdrawal of metformin once Covid-19 infection becomes severe represents a reasonable and pragmatic precaution for metformin administration (Figure 4). Such an approach may reduce the potential for developing either life-threatening complications of Covid-19, or lactic acidosis events associated with metformin.

 Conclusion

People with diabetes are at a markedly increased risk of adverse outcomes related to Covid-19 infection. Retrospective data suggest that type 2 diabetes patients receiving treatment with metformin at the time of hospitalisation with Covid-19 infection appear to have better outcomes in terms of reduced need for intensive care and reduced mortality compared with patients not receiving metformin when admitted. While the literature does not distinguish between patients who continued or discontinued metformin during hospitalisation, evidence supports the use of metformin when Covid-19 infection is not severe. Due to the risk of hypoxaemia, acute renal disease, cardiovascular complications and acidosis, it is appropriate to consider withdrawing metformin when Covid-19 becomes more severe. Retrospective studies are by nature hypothesis generating, and there is a need for prospective study of the effects of metformin in people with Covid -19.

 Take Home Message

Metformin may be continued for most people with type 2 diabetes who present with milder forms of Covid-19, but should be withdrawn when Covid-19 becomes more severe to reduce the potential for aggravation of the risk of acidosis and hypoxaemia.

 Author Contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

 Funding

Merck Healthcare KGaA, darmstadt, Germany, funded the APC for this article. MG, received funding from Merck KGaA, Darmstadt in support of the preparation of this review.

 Conflict of Interest

CB declared no duality of interest associated with this manuscript. MG has previously provided paid editorial support services to Merck KGaA, a pharmaceutical sponsor of metformin. No funding applied to the development of this article, and no organisation or individual other than the authors had any role in its development.

 Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Abdi A. Jalilian M. Sarbarzeh P. A. Vlaisavljevic Z. (2020). Diabetes and COVID-19: A Systematic Review on the Current Evidences. Diabetes Res. Clin. Pract. 166, 108347. 10.1016/j.diabres.2020.108347 Abu-Jamous B. Anisimovich A. Baxter J. Mackillop L. Vizcaychipi M. P. McCarthy A. (2021). Associations of Comorbidities and Medications with COVID-19 Outcome: A Retrospective Analysis of Real-World Evidence Data. Preprint available at https://www.medrxiv.org/content/10.1101/2020.08.20.20174169v1.full (Accessed April, 2021). Aggarwal G. Lippi G. Lavie C. J. Henry B. M. Sanchis-Gomar F. (2020). Diabetes Mellitus Association with Coronavirus Disease 2019 (COVID-19) Severity and Mortality: A Pooled Analysis. J. Diabetes 12, 851–855. 10.1111/1753-0407.13091 Al-Kuraishy H. M. Al-Gareeb A. I. Alblihed M. Cruz-Martins N. Batiha G. E. (2021). COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients with Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin. Front. Med. (Lausanne) 8, 644295. 10.3389/fmed.2021.644295 Al-Salameh A. Lanoix J. P. Bennis Y. Andrejak C. Brochot E. Deschasse G. (2021). Characteristics and Outcomes of COVID-19 in Hospitalized Patients with and without Diabetes. Diabetes Metab. Res. Rev. 37, e3388. 10.1002/dmrr.3388 Ando W. Horii T. Uematsu T. Hanaki H. Atsuda K. Otori K. (2021). Impact of Overlapping Risks of Type 2 Diabetes and Obesity on Coronavirus Disease Severity in the United States. Sci. Rep. 11, 17968. 10.1038/s41598-021-96720-x Apicella M. Campopiano M. C. Mantuano M. Mazoni L. Coppelli A. Del Prato S. (2020). COVID-19 in People with Diabetes: Understanding the Reasons for Worse Outcomes. Lancet Diabetes Endocrinol. 8, 782–792. 10.1016/S2213-8587(20)30238-2 Bai B. Chen H. (2021). Metformin: a Novel Weapon against Inflammation. Front. Pharmacol. 12, 622262. 10.3389/fphar.2021.622262 Barron E. Bakhai C. Kar P. Weaver A. Bradley D. Ismail H. (2020). Associations of Type 1 and Type 2 Diabetes with COVID-19-Related Mortality in England: a Whole-Population Study. Lancet Diabetes Endocrinol. 8, 813–822. 10.1016/S2213-8587(20)30272-2 Bhatti R. Khamis A. H. Khatib S. Shiraz S. Matfin G. (2020). Clinical Characteristics and Outcomes of Patients with Diabetes Admitted for Covid-19 Treatment in Dubai: Single-Centre Cross-Sectional Study. JMIR Public Health Surveill. 6, e22471. 10.2196/22471 Bramante C. T. Ingraham N. E. Murray T. A. Marmor S. Hovertsen S. Gronski J. (2021b). Metformin and Risk of Mortality in Patients Hospitalised with COVID-19: a Retrospective Cohort Analysis. Lancet Healthy Longev 2, e34–41. 10.1016/S2666-7568(20)30033-7 Bramante C. T. Buse J. Tamaritz L. Palacio A. Cohen K. Vojta D. (2021a). Outpatient Metformin Use Is Associated with Reduced Severity of COVID‐19 Disease in Adults with Overweight or Obesity. J. Med. Virol. 93, 4273–4279. 10.1002/jmv.26873 Bud E. S. Vlasa A. Bud A. (2020). Diabetes Mellitus Is Associated with Severe Infection and Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis. Arch. Med. Res. S0188-4409 (20), 31688–X. 10.1016/j.arcmed.2020.11.003 Cai Y. Shi S. Yang F. Yi B. Chen X. Li J. (2020). Fasting Blood Glucose Level Is a Predictor of Mortality in Patients with COVID-19 Independent of Diabetes History. Diabetes Res. Clin. Pract. 169, 108437. 10.1016/j.diabres.2020.108437 Carey I. M. Critchley J. A. DeWilde S. Harris T. Hosking F. J. Cook D. G. (2018). Risk of Infection in Type 1 and Type 2 Diabetes Compared with the General Population: A Matched Cohort Study. Diabetes Care 41, 513–521. 10.2337/dc17-2131 Carrasco-Sánchez F. J. López-Carmona M. D. Martínez-Marcos F. J. Pérez-Belmonte L. M. Hidalgo-Jiménez A. Buonaiuto V. (2021). Admission Hyperglycaemia as a Predictor of Mortality in Patients Hospitalized with COVID-19 Regardless of Diabetes Status: Data from the Spanish SEMI-COVID-19 Registry. Ann. Med. 53, 103–116. 10.1080/07853890.2020.1836566 Centers for Disease Control (2020). National Diabetes Statistics Report. Estimates of Diabetes and its burden in the United States. Available at https://www.cdc.gov/diabetes/data/statistics-report/index.html (Accessed April, 2021). Chen J. Wu C. Wang X. Yu J. Sun Z. (2020). The Impact of COVID-19 on Blood Glucose: a Systematic Review and Meta-Analysis. Front. Endocrinol. (Lausanne) 11, 574541. 10.3389/fendo.2020.574541 Chen L. Chen R. Wang H. Liang F. (2015). Mechanisms Linking Inflammation to Insulin Resistance. Int. J. Endocrinol. 2015, 508409. 10.1155/2015/508409 Chen L. Y. C. Quach T. T. T. (2021). COVID-19 Cytokine Storm Syndrome: a Threshold Concept. Lancet Microbe 2, e49–e50. 10.1016/S2666-5247(20)30223-8 Chen Y. Yang D. Yang C. Zheng L. Huang K. (2020). Response to Comment on Chen et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care 2020;43:1399-1407. Diabetes Care 43, e165–407. 10.2337/dci20-0035 Cheng X. Liu Y. M. Li H. Zhang X. Lei F. Qin J. J. (2020). Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 32, 537–e3. e3. 10.1016/j.cmet.2020.08.013 Cheng X. Xin S. Chen Y. Li L. Chen W. Li W. (2021). Effects of Metformin, Insulin on COVID-19 Patients with Pre-existed Type 2 Diabetes: A Multicentral Retrospective Study. Life Sci. 275, 119371. 10.1016/j.lfs.2021.119371 Chilimuri S. Sun H. Alemam A. Mantri N. Shehi E. Tejada J. (2020). Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City. West. J. Emerg. Med. 21, 779–784. 10.5811/westjem.2020.6.47919 Chou P. Liao M. J. Kuo H. S. Hsiao K. J. Tsai S. T. (1994). A Population Survey on the Prevalence of Diabetes in Kin-Hu, Kinmen. Diabetes Care 17, 1055–1058. 10.2337/diacare.17.9.1055 Ciceri F. Castagna A. Rovere-Querini P. De Cobelli F. Ruggeri A. Galli L. (2020). Early Predictors of Clinical Outcomes of COVID-19 Outbreak in Milan, Italy. Clin. Immunol. 217, 108509. 10.1016/j.clim.2020.108509 Bailey C. J. Campbell I. W Chan J. C. N. Davidson J. A. Howlett H. C. S. Ritz P. Editors (2007). Metformin – the Gold Standard: A Scientific Handbook (Chichester (UK): Wiley). ISBN: 978-0-470-72644-0. Corona G. Pizzocaro A. Vena W. Rastrelli G. Semeraro F. Isidori A. M. (2021). Diabetes Is Most Important Cause for Mortality in COVID-19 Hospitalized Patients: Systematic Review and Meta-Analysis. Rev. Endocr. Metab. Disord. 22, 1–22. 10.1007/s11154-021-09630-8 Covid live (2021). Covid Live Update. Available at: https://www.worldometers.info/coronavirus/ (Accessed December, 2021). Crouse A. B. Grimes T. Li P. Might M. Ovalle F. Shalev A. (2020). Metformin Use Is Associated with Reduced Mortality in a Diverse Population with COVID-19 and Diabetes. Front. Endocrinol. (Lausanne) 11, 600439. 10.3389/fendo.2020.600439 DeFronzo R. Fleming G. A. Chen K. Bicsak T. A. (2016). Metformin-associated Lactic Acidosis: Current Perspectives on Causes and Risk. Metabolism 65, 20–29. 10.1016/j.metabol.2015.10.014 Desai R. Singh S. Parekh T. Sachdeva S. Sachdeva R. Kumar G. (2020). COVID-19 and Diabetes Mellitus: A Need for Prudence in Elderly Patients from a Pooled Analysis. Diabetes Metab. Syndr. 14, 683–685. 10.1016/j.dsx.2020.05.021 Diedisheim M. Dancoisne E. Gautier J. F. Larger E. Cosson E. Fève B. (2021). Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults. J. Clin. Endocrinol. Metab. 106, e3364–e3368. 10.1210/clinem/dgab393 Do J. Y. Kim S. W. Park J. W. Cho K. H. Kang S. H. (2020). Is There an Association between Metformin Use and Clinical Outcomes in Diabetes Patients with COVID-19. Diabetes Metab. 47, 101208. 10.1016/j.diabet.2020.10.006 Docherty A. B. Harrison E. M. Green C. A. Hardwick H. E. Pius R. Norman L. (2020). Features of 20 133 UK Patients in Hospital with Covid-19 Using the ISARIC WHO Clinical Characterisation Protocol: Prospective Observational Cohort Study. BMJ 369, m1985. 10.1136/bmj.m1985 Dokken B. B. (2008). The Pathophysiology of Cardiovascular Disease and Diabetes: beyond Blood Pressure and Lipids. Diabetes Spectr. 21, 160–165. 10.2337/diaspect.21.3.160 Du Q. Wu B. Wang Y. J. Yang S. Zhao Y. Y. Liang Y. Y. (2013). Comparative Effects of Sitagliptin and Metformin in Patients with Type 2 Diabetes Mellitus: a Meta-Analysis. Curr. Med. Res. Opin. 29, 1487–1494. 10.1185/03007995.2013.833090 Elezkurtaj S. Greuel S. Ihlow J. Michaelis E. G. Bischoff P. Kunze C. A. (2021). Causes of Death and Comorbidities in Hospitalized Patients with COVID-19. Sci. Rep. 11, 4263. 10.1038/s41598-021-82862-5 Fadini G. P. Morieri M. L. Boscari F. Fioretto P. Maran A. Busetto L. (2020). Newly-diagnosed Diabetes and Admission Hyperglycemia Predict COVID-19 Severity by Aggravating Respiratory Deterioration. Diabetes Res. Clin. Pract. 168, 108374. 10.1016/j.diabres.2020.108374 Feldman E. L. Savelieff M. G. Hayek S. S. Pennathur S. Kretzler M. Pop-Busui R. (2020). COVID-19 and Diabetes: A Collision and Collusion of Two Diseases. Diabetes 69, 2549–2565. 10.2337/dbi20-0032 Fox T. Ruddiman K. Lo K. B. Peterson E. DeJoy R. Salacup G. (2021). The Relationship between Diabetes and Clinical Outcomes in COVID-19: a Single-center Retrospective Analysis. Acta Diabetol. 58, 33–38. 10.1007/s00592-020-01592-8 Gao Y. Liu T. Zhong W. Liu R. Zhou H. Huang W. (2020). Risk of Metformin in Patients with Type 2 Diabetes with COVID-19: A Preliminary Retrospective Report. Clin. Transl Sci. 13, 1055–1059. 10.1111/cts.12897 Ghany R. Palacio A. Dawkins E. Chen G. McCarter D. Forbes E. (2021). Metformin Is Associated with Lower Hospitalizations, Mortality and Severe Coronavirus Infection Among Elderly Medicare Minority Patients in 8 States in USA. Diabetes Metab. Syndr. 15, 513–518. 10.1016/j.dsx.2021.02.022 Gianchandani R. Esfandiari N. H. Ang L. Iyengar J. Knotts S. Choksi P. (2020). Managing Hyperglycemia in the COVID-19 Inflammatory Storm. Diabetes 69, 2048–2053. 10.2337/dbi20-0022 Govender N. Khaliq O. P. Moodley J. Naicker T. (2021). Insulin Resistance in COVID-19 and Diabetes. Prim. Care Diabetes 15 (4), 629–634. 10.1016/j.pcd.2021.04.004 Grant P. J. (2003). Beneficial Effects of Metformin on Haemostasis and Vascular Function in Man. Diabetes Metab. 29, 6S44–52. 10.1016/s1262-3636(03)72787-6 Gregory J. M. Slaughter J. C. Duffus S. H. Smith T. J. LeStourgeon L. M. Jaser S. S. (2021). Response to Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526-532. Diabetes Care 44, e103–532. 10.2337/dci21-0005 Guan W. J. Liang W. H. Zhao Y. Liang H. R. Chen Z. S. Li Y. M. (2020). Comorbidity and its Impact on 1590 Patients with COVID-19 in China: a Nationwide Analysis. Eur. Respir. J. 55, 2000547. 10.1183/13993003.00547-2020 Guan Y. Wang D. Bu H. Zhao T. Wang H. (2020). The Effect of Metformin on Polycystic Ovary Syndrome in Overweight Women: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int. J. Endocrinol. 2020, 5150684. 10.1155/2020/5150684 Guo L. Shi Z. Zhang Y. Wang C. Do Vale Moreira N. C. Zuo H. (2020). Comorbid Diabetes and the Risk of Disease Severity or Death Among 8807 COVID-19 Patients in China: A Meta-Analysis. Diabetes Res. Clin. Pract. 166, 108346. 10.1016/j.diabres.2020.108346 Guo W. Li M. Dong Y. Zhou H. Zhang Z. Tian C. (2020). Diabetes Is a Risk Factor for the Progression and Prognosis of COVID-19. Diabetes Metab. Res. Rev., e3319. 10.1002/dmrr.3319 Han Y. Xie H. Liu Y. Gao P. Yang X. Shen Z. (2019). Effect of Metformin on All-Cause and Cardiovascular Mortality in Patients with Coronary Artery Diseases: a Systematic Review and an Updated Meta-Analysis. Cardiovasc. Diabetol. 18, 96. 10.1186/s12933-019-0900-7 Hawley S. A. Gadalla A. E. Olsen G. S. Hardie D. G. (2002). The Antidiabetic Drug Metformin Activates the AMP-Activated Protein Kinase cascade via an Adenine Nucleotide-independent Mechanism. Diabetes 51, 2420–2425. 10.2337/diabetes.51.8.2420 Hostalek U. Campbell I. (2021). Metformin for Diabetes Prevention: Update of the Evidence Base. Curr. Med. Res. Opin. 37, 1705–1717. 10.1080/03007995.2021.1955667 Hostalek U. Gwilt M. Hildemann S. (2015). Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs 75, 1071–1094. 10.1007/s40265-015-0416-8 Huang I. Lim M. A. Pranata R. (2020). Diabetes Mellitus Is Associated with Increased Mortality and Severity of Disease in COVID-19 Pneumonia - A Systematic Review, Meta-Analysis, and Meta-Regression. Diabetes Metab. Syndr. 14, 395–403. 10.1016/j.dsx.2020.04.018 Huang Y. Guo H. Zhou Y. Guo J. Wang T. Zhao X. (2020). The Associations between Fasting Plasma Glucose Levels and Mortality of COVID-19 in Patients without Diabetes. Diabetes Res. Clin. Pract. 169, 108448. 10.1016/j.diabres.2020.108448 Hussain S. Baxi H. Chand Jamali M. Nisar N. Hussain M. S. (2020). Burden of Diabetes Mellitus and its Impact on COVID-19 Patients: A Meta-Analysis of Real-World Evidence. Diabetes Metab. Syndr. 14, 1595–1602. 10.1016/j.dsx.2020.08.014 Campbell I. W. Howlett H. C. S. Holman R. R. Bailey C. J. (Editors) (2017). “Metformin – 60 Years of Clinical Experience,” Addendum to the Scientific Handbook (Chichester (UK): Wiley), 1–122. ISBN 978-3-527-34449-9 2017. Jiang N. Chen Z. Liu L. Yin X. Yang H. Tan X. (2021). Association of Metformin with Mortality or ARDS in Patients with COVID-19 and Type 2 Diabetes: A Retrospective Cohort Study. Diabetes Res. Clin. Pract. 173, 108619. 10.1016/j.diabres.2020.108619 Jornayvaz F. R. Assouline B. Pugin J. Gariani K. (2020). Extremely High-Dose Insulin Requirement in a Diabetic Patient with COVID-19: a Case Report. BMC Endocr. Disord. 20, 155. 10.1186/s12902-020-00632-2 Kaminska H. Szarpak L. Kosior D. Wieczorek W. Szarpak A. Al-Jeabory M. (2021). Impact of Diabetes Mellitus on In-Hospital Mortality in Adult Patients with COVID-19: a Systematic Review and Meta-Analysis. Acta Diabetol. 58, 1101–1110. 10.1007/s00592-021-01701-1 Kathuria D. Raul A. D. Wanjari P. Bharatam P. V. (2021). Biguanides: Species with Versatile Therapeutic Applications. Eur. J. Med. Chem. 219, 113378. 10.1016/j.ejmech.2021.113378 Kim M. K. Jeon J. H. Kim S. W. Moon J. S. Cho N. H. Han E. (2020). The Clinical Characteristics and Outcomes of Patients with Moderate-To-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea. Diabetes Metab. J. 44, 602–613. 10.4093/dmj.2020.0146 Kow C. S. Hasan S. S. (2021). Mortality Risk with Preadmission Metformin Use in Patients with COVID-19 and Diabetes: A Meta-Analysis. J. Med. Virol. 93, 695–697. 10.1002/jmv.26498 Kumar A. Arora A. Sharma P. Anikhindi S. A. Bansal N. Singla V. (2020). Reply to the letter of Singh and Singh in response to the article: "Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis" (Kumar et al). Diabetes Metab. Syndr. 14, 1147–1148. 10.1016/j.dsx.2020.07.002 Lalau J. D. Al-Salameh A. Hadjadj S. Goronflot T. Wiernsperger N. Pichelin M. (2021). Metformin Use Is Associated with a Reduced Risk of Mortality in Patients with Diabetes Hospitalised for COVID-19. Diabetes Metab. 47, 101216. 10.1016/j.diabet.2020.101216 Lally M. A. Tsoukas P. Halladay C. W. O'Neill E. Gravenstein S. Rudolph J. L. (2021). Metformin Is Associated with Decreased 30-Day Mortality Among Nursing Home Residents Infected with SARS-CoV2. J. Am. Med. Dir. Assoc. 22, 193–198. 10.1016/j.jamda.2020.10.031 Lee J. Y. Kim H. A. Huh K. Hyun M. Rhee J. Y. Jang S. (2020). Risk Factors for Mortality and Respiratory Support in Elderly Patients Hospitalized with COVID-19 in Korea. J. Korean Med. Sci. 35, e223. 10.3346/jkms.2020.35.e223 Li J. Wei Q. Li W. X. McCowen K. C. Xiong W. Liu J. (2020). Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19. Endocr. Pract. 26, 1166–1172. 10.4158/EP-2020-0466 Li W. Li J. Wei Q. McCowen K. Xiong W. Liu J. (2021). Inpatient Use of Metformin and Acarbose Is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus. Res. Sq, Advance Publication Online. 10.21203/rs.3.rs-287308/v1 Lim S. Bae J. H. Kwon H. S. Nauck M. A. (2021). COVID-19 and Diabetes Mellitus: from Pathophysiology to Clinical Management. Nat. Rev. Endocrinol. 17, 11–30. 10.1038/s41574-020-00435-4 Ling P. Luo S. Zheng X. Cai G. Weng J. (2021). Elevated Fasting Blood Glucose within the First Week of Hospitalization Was Associated with Progression to Severe Illness of COVID-19 in Patients with Preexisting Diabetes: A Multicenter Observational Study. J. Diabetes 13, 89–93. 10.1111/1753-0407.13121 Liu T. Zhang L. Joo D. Sun S. C. (2017). NF-κB Signaling in Inflammation. Signal. Transduct Target. Ther. 2, 17023. 10.1038/sigtrans.2017.23 Liu Y. Lu R. Wang J. Cheng Q. Zhang R. Zhang S. (2021). Diabetes, Even Newly Defined by HbA1c Testing, Is Associated with an Increased Risk of In-Hospital Death in Adults with COVID-19. BMC Endocr. Disord. 21, 56. 10.1186/s12902-021-00717-6 Liu Z. Li J. Huang J. Guo L. Gao R. Luo K. (2020). Association between Diabetes and COVID-19: A Retrospective Observational Study with a Large Sample of 1,880 Cases in Leishenshan Hospital, Wuhan. Front. Endocrinol. (Lausanne) 11, 478. 10.3389/fendo.2020.00478 Lukito A. A. Pranata R. Henrina J. Lim M. A. Lawrensia S. Suastika K. (2020). The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 Patients: a Systematic Review and Meta-Analysis. Diabetes Metab. Syndr. 14, 2177–2183. 10.1016/j.dsx.2020.11.006 Luo P. Qiu L. Liu Y. Liu X. L. Zheng J. L. Xue H. Y. (2020). Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis. Am. J. Trop. Med. Hyg. 103, 69–72. 10.4269/ajtmh.20-0375 Madjid M. Safavi-Naeini P. Solomon S. D. Vardeny O. (2020). Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 5, 831–840. 10.1001/jamacardio.2020.1286 Malhotra A. Hepokoski M. McCowen K. C. Y-J Shyy J. (2020). ACE2, Metformin, and COVID-19. iScience 23, 101425. 10.1016/j.isci.2020.101425 Mantovani A. Byrne C. D. Zheng M. H. Targher G. (2020). Diabetes as a Risk Factor for Greater COVID-19 Severity and In-Hospital Death: A Meta-Analysis of Observational Studies. Nutr. Metab. Cardiovasc. Dis. 30, 1236–1248. 10.1016/j.numecd.2020.05.014 Markowicz-Piasecka M. Sadkowska A. Huttunen K. M. Podsiedlik M. Mikiciuk-Olasik E. Sikora J. (2020). An Investigation into the Pleiotropic Activity of Metformin. A Glimpse of Haemostasis. Eur. J. Pharmacol. 872, 172984. 10.1016/j.ejphar.2020.172984 Miller L. E. Bhattacharyya R. Miller A. L. (2020). Diabetes Mellitus Increases the Risk of Hospital Mortality in Patients with Covid-19: Systematic Review with Meta-Analysis. Medicine (Baltimore) 99, e22439. 10.1097/MD.0000000000022439 Müller J. A. Groß R. Conzelmann C. Krüger J. Merle U. Steinhart J. (2021). SARS-CoV-2 Infects and Replicates in Cells of the Human Endocrine and Exocrine Pancreas. Nat. Metab. 3, 149–165. 10.1038/s42255-021-00347-1 Nadim M. K. Forni L. G. Mehta R. L. Connor M. J. Liu K. D. Ostermann M. (2020). COVID-19-associated Acute Kidney Injury: Consensus Report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat. Rev. Nephrol. 16, 747–764. 10.1038/s41581-020-00356-5 Nafakhi H. Alareedh M. Al-Buthabhak K. Shaghee F. Nafakhi A. Kasim S. (2021). Predictors of Adverse In-Hospital Outcome and Recovery in Patients with Diabetes Mellitus and COVID-19 Pneumonia in Iraq. Diabetes Metab. Syndr. 15, 33–38. 10.1016/j.dsx.2020.12.014 O'Malley G. Ebekozien O. Desimone M. Pinnaro C. T. Roberts A. Polsky S. (2021). COVID-19 Hospitalization in Adults with Type 1 Diabetes: Results from the T1D Exchange Multicenter Surveillance Study. J. Clin. Endocrinol. Metab. 106 (2), e936–e942. 10.1210/clinem/dgaa825 Oh T. K. Song I. A. (2021). Metformin Use and Risk of COVID-19 Among Patients with Type II Diabetes Mellitus: an NHIS-COVID-19 Database Cohort Study. Acta Diabetol. 58, 771–778. 10.1007/s00592-020-01666-7 Palaiodimos L. Chamorro-Pareja N. Karamanis D. Li W. Zavras P. D. Chang K. M. (2020). Diabetes Is Associated with Increased Risk for In-Hospital Mortality in Patients with COVID-19: a Systematic Review and Meta-Analysis Comprising 18,506 Patients. Hormones (Athens) 20, 1–10. 10.1007/s42000-020-00246-2 Parveen R. Sehar N. Bajpai R. Agarwal N. B. (2020). Association of Diabetes and Hypertension with Disease Severity in Covid-19 Patients: A Systematic Literature Review and Exploratory Meta-Analysis. Diabetes Res. Clin. Pract. 166, 108295. 10.1016/j.diabres.2020.108295 Pérez-Belmonte L. M. Torres-Peña J. D. López-Carmona M. D. Ayala-Gutiérrez M. M. Fuentes-Jiménez F. Huerta L. J. (2020). Mortality and Other Adverse Outcomes in Patients with Type 2 Diabetes Mellitus Admitted for COVID-19 in Association with Glucose-Lowering Drugs: a Nationwide Cohort Study. BMC Med. 18, 359. 10.1186/s12916-020-01832-2 Petrie J. R. Rossing P. R. Campbell I. W. (2020). Metformin and Cardiorenal Outcomes in Diabetes: A Reappraisal. Diabetes Obes. Metab. 22, 904–915. 10.1111/dom.13984 Petrilli C. M. Jones S. A. Yang J. Rajagopalan H. O'Donnell L. Chernyak Y. (2020). Factors Associated with Hospital Admission and Critical Illness Among 5279 People with Coronavirus Disease 2019 in New York City: Prospective Cohort Study. BMJ 369, m1966. 10.1136/bmj.m1966 Raveendran A. V. Misra A. (2021). Post COVID-19 Syndrome ("Long COVID") and Diabetes: Challenges in Diagnosis and Management. Diabetes Metab. Syndr. 15, 102235. 10.1016/j.dsx.2021.102235 Rawshani A. Kjölhede E. A. Rawshani A. Sattar N. Eeg-Olofsson K. Adiels M. (2021). Severe COVID-19 in People with Type 1 and Type 2 Diabetes in Sweden: A Nationwide Retrospective Cohort Study. Lancet Reg. Health Eur. 4, 100105. 10.1016/j.lanepe.2021.100105 Roberts J. Pritchard A. L. Treweeke A. T. Rossi A. G. Brace N. Cahill P. (2020). Why Is COVID-19 More Severe in Patients with Diabetes? the Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. Front. Cardiovasc. Med. 7, 629933. 10.3389/fcvm.2020.629933 Rodrigues Prestes T. R. Rocha N. P. Miranda A. S. Teixeira A. L. Simoes-E-Silva A. C. (2017). The Anti-inflammatory Potential of ACE2/angiotensin-(1-7)/Mas Receptor axis: Evidence from Basic and Clinical Research. Curr. Drug Targets 18, 1301–1313. 10.2174/1389450117666160727142401 Roncon L. Zuin M. Rigatelli G. Zuliani G. (2020). Diabetic Patients with COVID-19 Infection Are at Higher Risk of ICU Admission and Poor Short-Term Outcome. J. Clin. Virol. 127, 104354. 10.1016/j.jcv.2020.104354 Rukavina Mikusic N. L. Silva M. G. Mazzitelli L. R. Santos R. A. S. Gómez K. A. Grecco H. E. (2021). Interaction between the Angiotensin-(1-7) Mas Receptor and the Dopamine D2 Receptor: Implications in Inflammation. Hypertension 77, 1659–1669. 10.1161/HYPERTENSIONAHA.120.16614 Saand A. R. Flores M. Kewan T. Alqaisi S. Alwakeel M. Griffiths L. (2021). Does Inpatient Hyperglycemia Predict a Worse Outcome in COVID-19 Intensive Care Unit Patients? J. Diabetes 13, 253–260. 10.1111/1753-0407.13137 Saha S. Al-Rifai R. H. Saha S. (2021). Diabetes Prevalence and Mortality in COVID-19 Patients: a Systematic Review, Meta-Analysis, and Meta-Regression. J. Diabetes Metab. Disord. 20, 939–950. 10.1007/s40200-021-00779-2 Saisho Y. (2015). Metformin and Inflammation: Its Potential beyond Glucose-Lowering Effect. Endocr. Metab. Immune Disord. Drug Targets 15, 196–205. 10.2174/1871530315666150316124019 Salminen A. Hyttinen J. M. Kaarniranta K. (2011). AMP-activated Protein Kinase Inhibits NF-Κb Signaling and Inflammation: Impact on Healthspan and Lifespan. J. Mol. Med. (Berl) 89, 667–676. 10.1007/s00109-011-0748-0 Sathish T. Cao Y. (2021). Is Newly Diagnosed Diabetes as Frequent as Preexisting Diabetes in COVID-19 Patients? Diabetes Metab. Syndr. 15, 147–148. 10.1016/j.dsx.2020.12.024 Sathish T. Kapoor N. Cao Y. Tapp R. J. Zimmet P. (2021). Proportion of Newly Diagnosed Diabetes in COVID-19 Patients: A Systematic Review and Meta-Analysis. Diabetes Obes. Metab. 23, 870–874. 10.1111/dom.14269 Seiglie J. Platt J. Cromer S. J. Bunda B. Foulkes A. S. Bassett I. V. (2020). Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized with COVID-19. Diabetes Care 43, 2938–2944. 10.2337/dc20-1506 Shang J. Wang Q. Zhang H. Wang X. Wan J. Yan Y. (2021). The Relationship between Diabetes Mellitus and COVID-19 Prognosis: A Retrospective Cohort Study in Wuhan, China. Am. J. Med. 134, e6–e14. 10.1016/j.amjmed.2020.05.033 Shang L. Shao M. Guo Q. Shi J. Zhao Y. Xiaokereti J. (2020). Diabetes Mellitus Is Associated with Severe Infection and Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis. Arch. Med. Res. 51, 700–709. 10.1016/j.arcmed.2020.07.005 Shi Q. Zhang X. Jiang F. Zhang X. Hu N. Bimu C. (2020). Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients with Diabetes in Wuhan, China: a two-center, Retrospective Study. Diabetes Care 43, 1382–1391. 10.2337/dc20-0598 Singh A. K. Gupta R. Ghosh A. Misra A. (2020). Diabetes in COVID-19: Prevalence, Pathophysiology, Prognosis and Practical Considerations. Diabetes Metab. Syndr. 14, 303–310. 10.1016/j.dsx.2020.04.004 Smith A. A. Fridling J. Ibrahim D. Porter P. S. Jr (2020). Identifying Patients at Greatest Risk of Mortality Due to COVID-19: A New England Perspective. West. J. Emerg. Med. 21, 785–789. 10.5811/westjem.2020.6.47957 Sun Y. Guan X. Jia L. Xing N. Cheng L. Liu B. (2021). Independent and Combined Effects of Hypertension and Diabetes on Clinical Outcomes in Patients with COVID‐19: A Retrospective Cohort Study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital. J. Clin. Hypertens. 23, 218–231. 10.1111/jch.14146 UK Prospective Diabetes Study (UKPDS) Group (1998). Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854–865. 10.1016/S0140-6736(98)07037-8 Varikasuvu S. R. Dutt N. Thangappazham B. Varshney S. (2021). Diabetes and COVID-19: A Pooled Analysis Related to Disease Severity and Mortality. Prim. Care Diabetes 15, 24–27. 10.1016/j.pcd.2020.08.015 Vial G. Detaille D. Guigas B. (2019). Role of Mitochondria in the Mechanism(s) of Action of Metformin. Front. Endocrinol. (Lausanne) 10, 294. 10.3389/fendo.2019.00294 Wang B. Glicksberg B. S. Nadkarni G. N. Vashishth D. (2021). Evaluation and Management of COVID-19-Related Severity in People with Type 2 Diabetes. BMJ Open Diabetes Res. Care 9, e002299. 10.1136/bmjdrc-2021-002299 Wang J. Cooper J. M. Gokhale K. Acosta-Mena D. Dhalla S. Byne N. (2021). Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes. J. Clin. Endocrinol. Metab. 106 (5), 1255–1268. 10.1210/clinem/dgab067 Wang Y. Yu M. Xu S. Zhao J. Li N. Zhou M. (2020). Risk Factors for Poor Outcomes of Diabetes Patients with COVID-19: A Single-Center, Retrospective Study in Early Outbreak in China. Front. Endocrinol. (Lausanne) 11, 571037. 10.3389/fendo.2020.571037 Wargny M. Potier L. Gourdy P. Pichelin M. Amadou C. Benhamou P. Y. (2021). Predictors of Hospital Discharge and Mortality in Patients with Diabetes and COVID-19: Updated Results from the Nationwide CORONADO Study. Diabetologia 64, 778–794. 10.1007/s00125-020-05351-w Wu C. Chen X. Cai Y. Xia J. Zhou X. Xu S. (2020). Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 180, 934–943. 10.1001/jamainternmed.2020.0994 Wu J. Zhang J. Sun X. Wang L. Xu Y. Zhang Y. (2020). Influence of Diabetes Mellitus on the Severity and Fatality of SARS-CoV-2 (COVID-19) Infection. Diabetes Obes. Metab. 22, 1907–1914. 10.1111/dom.14105 Wu Z. H. Tang Y. Cheng Q. (2021). Diabetes Increases the Mortality of Patients with COVID-19: a Meta-Analysis. Acta Diabetol. 58, 139–144. 10.1007/s00592-020-01546-0 Xin G. Wei Z. Ji C. Zheng H. Gu J. Ma L. (2016). Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release. Sci. Rep. 6, 36222. 10.1038/srep36222 Xu Z. Wang Z. Wang S. Ye Y. Luo D. Wan L. (2020). The Impact of Type 2 Diabetes and its Management on the Prognosis of Patients with Severe COVID-19. J. Diabetes 12, 909–918. 10.1111/1753-0407.13084 Yan Y. Yang Y. Wang F. Ren H. Zhang S. Shi X. (2020). Clinical Characteristics and Outcomes of Patients with Severe Covid-19 with Diabetes. BMJ Open Diabetes Res. Care 8, e001343. 10.1136/bmjdrc-2020-001343 Yu C. Lei Q. Li W. Wang X. Liu W. Fan X. (2020). Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: a Retrospective Study in Wuhan, China. Am. J. Prev. Med. 59, 168–175. 10.1016/j.amepre.2020.05.002 Zaki N. Alashwal H. Ibrahim S. (2020). Association of Hypertension, Diabetes, Stroke, Cancer, Kidney Disease, and High-Cholesterol with COVID-19 Disease Severity and Fatality: A Systematic Review. Diabetes Metab. Syndr. 14 (5), 1133–1142. 10.1016/j.dsx.2020.07.005 Zangiabadian M. Nejadghaderi S. A. Zahmatkesh M. M. Hajikhani B. Mirsaeidi M. Nasiri M. J. (2021). The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: a Systematic Review. Front. Endocrinol. 12, 645194. 10.3389/fendo.2021.645194 Zhang J. Dong J. Martin M. He M. Gongol B. Marin T. L. (2018). AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension. Am. J. Respir. Crit. Care Med. 198, 509–520. 10.1164/rccm.201712-2570OC Zhang K. Yang W. Dai H. Deng Z. (2020). Cardiovascular Risk Following Metformin Treatment in Patients with Type 2 Diabetes Mellitus: Results from Meta-Analysis. Diabetes Res. Clin. Pract. 160, 108001. 10.1016/j.diabres.2020.108001 Zhang Q. Wei Y. Chen M. Wan Q. Chen X. (2020). Clinical Analysis of Risk Factors for Severe COVID-19 Patients with Type 2 Diabetes. J. Diabetes Complications 34, 107666. 10.1016/j.jdiacomp.2020.107666 Zhang W. Li C. Xu Y. He B. Hu M. Cao G. (2021). Hyperglycemia and Correlated High Levels of Inflammation Have a Positive Relationship with the Severity of Coronavirus Disease 2019. Mediators Inflamm. 2021, 8812304. 10.1155/2021/8812304 Zhang Y. Cui Y. Shen M. Zhang J. Liu B. Dai M. (2020a). Association of Diabetes Mellitus with Disease Severity and Prognosis in COVID-19: A Retrospective Cohort Study. Diabetes Res. Clin. Pract. 165, 108227. 10.1016/j.diabres.2020.108227 Zhang Y. Li H. Zhang J. Cao Y. Zhao X. Yu N. (2020b). The Clinical Characteristics and Outcomes of Patients with Diabetes and Secondary Hyperglycaemia with Coronavirus Disease 2019: A single-centre, Retrospective, Observational Study in Wuhan. Diabetes Obes. Metab. 22, 1443–1454. 10.1111/dom.14086 Zhou F. Yu T. Du R. Fan G. Liu Y. Liu Z. (2020). Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: a Retrospective Cohort Study. Lancet 395, 1054–1062. 10.1016/S0140-6736(20)30566-3 Zhu L. She Z. G. Cheng X. Qin J. J. Zhang X. J. Cai J. (2020). Association of Blood Glucose Control and Outcomes in Patients with Covid-19 and Pre-existing Type 2 Diabetes. Cel Metab 31, 1068–e3. 10.1016/j.cmet.2020.04.021